Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia

Abstract

Background: Blinatumomab early-line treatment in B-cell precursor acute lymphoblastic leukemia (B-ALL) might improve clinical outcomes. Methods: We conducted a retrospective real-world cohort analysis in 20 newly diagnosed B-ALL patients who received reduced-dose chemotherapy (idarubicin, vindesine, and dexamethasone) for 1–3 weeks, followed by blinatumomab for 1–4 weeks as an induction therapy. Results: At the end of the induction therapy, a complete remission rate of 100% was achieved; 17 (85%) patients were minimal residual disease (MRD) negative (<1 × 10−4). Adverse events (AEs) were reported in 12 (60%) patients—43.8% were grade 1–2 and 56.2% were grade 3–4. No incidence of neurotoxicity or grade ≥3 cytokine release syndrome was reported. Conclusions: Blinatumomab demonstrated a significant improvement in clinical outcomes in patients with newly diagnosed B-ALL irrespective of their poor-risk factor status and the pretreatment blast burden.